Assess the current state of global pandemic preparedness infrastructure post-COVID, identify the critical gaps in disease surveillance, diagnostic capacity, and vaccine manufacturing redundancy, and quantify the investment required to prevent a repeat of 2020 supply shocks.

Analysis of WHO pandemic preparedness scorecard data across 195 countries, CDC disease surveillance network capacity assessment, WHO-convened pathogen research platform database, and GAVI vaccine manufacturing capacity tracking. Cross-referenced with cost-benefit analysis from Johns Hopkins Center for Health Security and McKinsey pandemic preparedness studies.

Despite three years post-COVID, 147 of 195 countries lack a functional integrated disease surveillance system. mRNA vaccine manufacturing capacity outside of Pfizer, Moderna, and Biontech remains minimal — only 15 countries have licensed mRNA manufacturing facilities, all concentrated in high-income nations.

The global diagnostic testing capacity that was painfully mobilized in 2020 has since been defunded; PCR machines installed in 2020 are now sitting idle or decommissioned. The cost of building redundant pandemic response infrastructure — surveillance networks, diagnostic hubs, distributed manufacturing capacity in each WHO region — is estimated at $50 billion over 10 years.

The annual recurring cost of maintaining readiness is estimated at $5 billion globally, yet current spending is less than $2 billion.